Antisense, RNA
Antisense, RNA Companies (3)
Antisense, RNA News
-
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine -
News BioNTech to start work on first African mRNA vaccine factory this month
The Rwanda site will be the first piece of the company’s African manufacturing network
Antisense, RNA Products (5)
-
Product Oligonucleotide Analytical Development Services
Analytical development services for oligonucleotides: For oligo-based drugs, our capabilities range from GLP bioanalysis to GLP/cGMP characterisation. We support product development, from quality control testing of amidite starting materials and early stage product characterization through to GMP batch rele... -
Product Oligonucleotide Process Development and Manufacturing
WuXi STA has an integrated Oligo API process R&D and manufacturing platform from preclinical to commercial, operating at our US FDA inspected integrated process R&D and manufacturing facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modaliti... -
Product Large Molecule Discovery & Development Services
We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities suc... -
Product mRNA Characterisation and Analysis
Characterization and analysis of mRNA supporting vaccine and therapeutic development, including assessing clinical translation efficiency and immunogenicity. At our GLP / GCP / GMP laboratories, scientists can test a mRNA drug substance or drug product to help you confidently assess batch to batch manufactu... -
Product ATB-301
Combination therapy of TGF-β2 Targeting Antisense Oligonucleotide (TASO) + IL-2
ATB-301 is a new drug candidate for combined anti-cancer treatment of TGF-β selective inhibitor, TASO and IL-2.
In-vitro : Verified synergistic effect by TASO+IL-2 combination therapy on breast c...
Upcoming Events
-
CPHI Korea 2022
COEX, Seoul, Korea
28 - 30 September 2022 -
CPHI Frankfurt 2022
Messe Frankfurt, Frankfurt, Germany
1-3 November 2022 -
CPHI & PMEC India 2022
India Expo Centre, Greater Noida, Delhi NCR
29 November - 1 December
Pharmaceutical Industry Webinars
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance